CNTA

NEUTRALM&A

Centessa Pharmaceuticals plc

2026-05-21

Price

$39.81

+0.15%

Score10.5Top Tier

Signals4/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.4xvs 20d avg

Analysis

Centessa's price action is structurally pegged to a definitive M&A agreement with Eli Lilly, which offered $38.00 in cash plus a $9.00 Contingent Value Right (CVR). The robust technical signals (ALPHA_MALE, QUIET_STORM) and uniquely low 2.2% realized volatility directly reflect this M&A arbitrage floor, with the stock trading at $39.81 to price in ~$1.81 of the CVR's probability. This represents High-Conviction Price Discovery as the market focuses entirely on the regulatory milestones for CNTA's orexin agonist pipeline. Furthermore, the highly accommodative RISK_ON macro regime and rock-bottom credit spreads ensure virtually zero financing or execution risk for the acquisition, cementing the deal's Q3 2026 completion timeline.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSPERFECT STACKQUIET ACCUMULATION

Key Takeaways

M&A Arbitrage Anchor: CNTA's tight price action and stacked moving averages are structurally anchored by LLY's $38/share cash offer [2.2.4].
CVR Probability Pricing: At $39.81, the market is assigning roughly $1.81 of value to the $9.00 CVR, which requires FDA approvals for sleep-wake disorder treatments.
Macro Tailwinds for Deal Close: The RISK_ON environment and tight credit spreads (0.75% OAS) minimize any M&A financing or execution risks ahead of the Q3 2026 close.

← Back to 2026-05-21 View Full CNTA History →Yahoo Finance &nearr;